LY-215,840 is an ergoline and lysergamide derivative drug developed by Eli Lilly, which acts as a potent and selective antagonist at the serotonin 5-HT<sub>2</sub> and 5-HT<sub>7</sub> receptors. It has anti-hypertensive and muscle relaxant effects in animal studies.